Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02383927
Recruitment Status : Recruiting
First Posted : March 10, 2015
Last Update Posted : May 9, 2019
Sponsor:
Information provided by (Responsible Party):
Kura Oncology, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : October 2020